Q2 2026 Knight Therapeutics Inc Earnings Call Transcript
Key Points
- Record high first-half 2026 performance with revenues of $293 million, adjusted EBITDA of $52 million, and operating cash flow of $70 million.
- Promoted portfolio grew 36% on a constant currency basis, driven by successful execution of 17 product launches across Canada and Latin America.
- Raised 2026 revenue guidance to $540-$560 million (at least 20% growth) and reaffirmed adjusted EBITDA margin of at least 15%.
- Strong balance sheet with $110 million in cash and marketable securities, net cash of $87 million, and $280 million available under credit facility.
- Gross margin improved to 49% of revenues in Q2 2026, up from 46% in the prior year, driven by higher contribution from the Canadian business.
- Adjusted EBITDA per share increased 61% year-over-year in Q2 2026, reflecting strong operational leverage.
- Canadian launch pipeline products grew 189% in Q2 2026 per IQVIA data, indicating strong commercial traction.
- Company expects EBITDA margin improvement over the next few years as launch products mature and infrastructure stabilizes.
- Received a notice of non-compliance from Health Canada for Crexant NDS, which may delay Canadian approval and require additional work with partner.
- Lenvima faces price controls in Colombia, with expectations of a material price decrease and potential generic competition later this year or early next.
- Q2 2026 financial assets recorded a net loss of $12 million due to mark-to-market revaluations of strategic fund and equity investments.
- Operating expenses increased 25% in Q2 2026 due to expansion in structure and spend to support launches and larger portfolio, pressuring margins.
- Ambisome sales to Brazilian MOH contributed significantly to H1 results, but no further sales are anticipated in H2 2026, creating a potential revenue gap.
- Qelbree NDS remains withdrawn, with no update on resubmission timeline, indicating ongoing regulatory uncertainty.
- Cash flow from operations can be lumpy quarter-to-quarter due to inventory purchases and onboarding of new assets, though expected to be healthy annually.
Good morning, ladies and gentlemen. My name is Matthew and I will be your operator today. Welcome to Knight Therapeutics Second Quarter 2026 Results Conference Call.
Before turning the call over to Samira Sakhia, President and CEO of Knight, listeners are reminded that portions of this discussion may, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward. Statements.
The company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the company and its subsidiaries may ultimately prove to be incorrect.
The company disclaims any intention or obligation to update or revise any forward-looking statements, whether a result of new information, future events, except as required by law.
We would also like to remind you questions during today's call will be taken from analysts only.
Should there
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
